NJ Medical Diagnostic Lab - 500+ Tests, $12.5M Revenue

$12.5M

Revenue

$1.3M

SDE

7.2x

Multiple

Subscribe Free

Read the full deal writeup

Get Free Access

Already a member? Sign in

Full Editorial Writeup

This is a fully equipped medical diagnostic laboratory based in New Jersey serving the broader tri-state area. The facility runs a menu of over 500 tests spanning molecular diagnostics and conventional clinical pathology, which means it is plugged into the everyday flow of physician orders, patient samples, and payer reimbursement. At $12.5M in annual revenue, this is a real operating business with infrastructure, accreditation, and referral relationships, not a startup.

The economics here are notable on the surface. The listing reports $1.25M in cash flow on $12.5M of revenue, which is a thin 10 percent margin for a diagnostics lab and worth scrutinizing closely given that high-volume labs with strong payer mix typically run materially higher. The seller is asking $9M, a 7.2x multiple on stated cash flow, which is rich for an SMB and signals the seller is pricing in the strategic value of the lab license, accreditation, equipment base, and the difficulty of building this from scratch.

Diagnostic labs are sticky, recurring-revenue businesses tied to ongoing healthcare demand rather than discretionary spend. The value lives in the CLIA certification, payer contracts, physician referral network, and the molecular testing capability, which is the higher-margin, higher-growth slice of the lab world. The buyer profile is someone who understands lab operations, reimbursement, and compliance, because this is a regulated business where the moat and the landmines are the same things.

Why we like it

Diagnostic testing is genuinely recession-resistant demand. Physicians order labs regardless of the economy, reimbursement comes largely from insurers and government payers, and a 500-test menu including molecular diagnostics covers both routine and higher-value work. This is recurring volume tied to healthcare utilization, not consumer sentiment.
The molecular diagnostics capability is the real asset. Molecular and PCR-based testing carries higher reimbursement and margin than routine chemistry panels, and standing up that capability requires equipment, validation, and accreditation that competitors cannot replicate quickly. That capability plus the CLIA license is the moat.
Regulatory barriers to entry protect the incumbent. A licensed, accredited, equipped lab with existing payer contracts and physician referral relationships is hard and slow to build from zero. That difficulty is exactly why the seller can credibly ask a 7.2x multiple instead of a typical SMB 3x to 4x.
Revenue scale provides operating leverage. At $12.5M of throughput, the fixed cost base of equipment, lab space, and credentialed staff is already absorbed, so incremental test volume drops to the bottom line at high margin. A buyer who adds referral sources or test menu can expand EBITDA meaningfully without proportional cost.

How to improve it

Audit the payer mix and reimbursement rates in the first 90 days. Labs live and die on contracted rates and denial rates, so pull the top payers by volume, identify out-of-network exposure, and quantify how much revenue is at risk from reimbursement cuts. This single analysis determines whether the 10 percent margin is fixable or structural.
Attack the thin margin directly. A diagnostics lab earning only 10 percent on $12.5M is leaving money on the table relative to well-run labs that clear 20 to 30 percent. Map labor cost per test, reagent and supply contracts, and reject-and-rerun rates, then renegotiate vendor pricing and optimize staffing to the actual test volume.
Shift mix toward high-value molecular and esoteric testing. Routine panels are commoditized and reimbursed poorly, while molecular diagnostics command premium rates. Use the existing molecular capability to expand the higher-margin menu and steer referral volume toward those tests.
Grow the physician referral base. Lab revenue is a function of how many ordering providers feed the funnel, so build a small outreach effort targeting physician groups, urgent care centers, and clinics in the tri-state footprint. Each new high-volume referring account is durable, recurring revenue.
Tighten revenue cycle management. Denials, slow collections, and coding errors silently erode lab margins. Implement disciplined claims scrubbing, denial appeals, and aging-AR follow-up to capture revenue that is currently being written off.
Pursue in-network contracts and additional payer credentialing. Out-of-network billing is volatile and increasingly squeezed, so converting to in-network status with major payers stabilizes revenue even if headline rates compress. Predictable cash flow is worth more than volatile spikes.

Diligence notes

Reconcile the margin story immediately. A 10 percent cash flow margin on a diagnostics lab is low and demands explanation. Determine whether it reflects heavy owner add-backs not yet captured, genuine operating inefficiency, declining reimbursement, or a one-time revenue spike that is now normalizing.
Verify CLIA certification, state licensure, and accreditation status. The entire enterprise value rests on the lab being properly licensed and in good standing with CMS and the state. Confirm no open compliance deficiencies, proficiency testing failures, or pending sanctions that could halt operations post-close.
Scrutinize revenue concentration and the molecular testing tail. Confirm whether the $12.5M is broad-based across many referring providers or concentrated in a few accounts or a single test type. If a meaningful share came from pandemic-era or one-off molecular volume, the run-rate could be materially lower than stated.
Examine reimbursement risk and billing compliance. Lab billing is a frequent target for payer audits and recoupment. Review the payer contracts, out-of-network exposure, historical denial rates, and any past or pending payer audits or fraud-and-abuse inquiries before trusting the cash flow.
Confirm the founding date, ownership history, and reason for sale. The listing omits years in business and seller motivation, which matters at a 7.2x ask. Understand who runs the medical directorship and key technical roles, since lab operations depend on credentialed personnel who may need to transfer or be replaced.
Validate equipment condition and lease versus owned facility. The lab is described as fully equipped, so verify the age, maintenance, and remaining useful life of analyzers and molecular instruments. Confirm whether the facility is leased and whether the lease transfers, since relocation of a licensed lab is costly and disruptive.

Source

Originally listed on BizBuySell. View original listing →